Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Mentz, Robert J; Bethel, M Angelyn; Gustavson, Stephanie M; Thompson, Vivian P; Pagidipati, Neha J.; Buse, John B.; Chan, Juliana C N; Iqbal, Nayyar; Maggioni, Aldo Pietro; Marso, Steve P; Öhman, Peter; Poulter, Neil; Ramachandran, Ambady; Zinman, Bernard; Hernandez, Adrian F.; Holman, Rury R

doi:10.1016/j.ahj.2017.02.005

Record: found
Abstract: found
Article: not found

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Author(s): Robert J Mentz ¹ , M Angelyn Bethel ² , Stephanie Gustavson ³ , Vivian P Thompson ⁴ , Neha J Pagidipati ⁴ , John B Buse ⁵ , Juliana C Chan ⁶ , Nayyar Iqbal ³ , Aldo P Maggioni ⁷ , Steve P Marso ⁸ , Peter Ohman ³ , Neil Poulter ⁹ , Ambady Ramachandran ¹⁰ , Bernard Zinman ¹¹ , Adrian F Hernandez ⁴ , Rury R Holman ²

Publication date (Electronic): May 2017

Journal: American heart journal

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

EXSCEL is a randomized, double-blind, placebo-controlled trial examining the effect of exenatide once-weekly (EQW) versus placebo on time to the primary composite outcome (cardiovascular death, nonfatal myocardial infarction or nonfatal stroke) in patients with type 2 diabetes mellitus (DM) and a wide range of cardiovascular (CV) risk.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am. Heart J.

Title: American heart journal

Publisher: Elsevier BV

ISSN (Electronic): 1097-6744

ISSN (Print): 0002-8703

Publication date (Electronic): May 2017

Volume: 187

Affiliations

[1 ] Duke Clinical Research Institute, Durham, NC. Electronic address: robert.mentz@duke.edu.

[2 ] Diabetes Trials Unit, University of Oxford, Oxford, UK.

[3 ] AstraZeneca Research and Development, Gaithersburg, MD.

[4 ] Duke Clinical Research Institute, Durham, NC.

[5 ] University of North Carolina at Chapel Hill, Chapel Hill, NC.

[6 ] The Chinese University of Hong Kong, Hong Kong, SAR, China.

[7 ] ANMCO Research Centre, Florence, Italy.

[8 ] University of Texas Southwestern Medical Center, Dallas, TX.

[9 ] International Centre for Circulatory Health, NHLI, Imperial College London, London, UK.

[10 ] India Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India.

[11 ] Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.

Article

Publisher Item ID: S0002-8703(17)30039-X

DOI: 10.1016/j.ahj.2017.02.005

PubMed ID: 28454792

SO-VID: b983fbaa-feea-45fc-853f-547e45cd96c3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 22

See all cited by

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Read this article at

Abstract

Related collections

Cardiovascular Innovations and Applications

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 96

Cited by 22